Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 31 Results

Title
Intervention Indication Therapeutic Area Year Actions
Enzalutamide (Xtandi) for non-metastatic prostate cancer Enzalutamide (Xtandi; MDV3100) Prostate cancer Male Reproductive Cancer 2017 View  |  Download
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy and/or radiotherapy Enzalutamide (Xtandi; MDV3100) Non-metastatic prostate cancer Male Reproductive Cancer 2022 View  |  Download
Enzalutamide in addition to androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer Enzalutamide (Xtandi; MDV3100) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Ipatasertib in combination with abiraterone and prednisone for metastatic castrate resistant prostate cancer – first line Abiraterone acetate (Zytiga; Yonsa) , Ipatasertib (GDC-0068; RG7440) , Prednisone (Decadron; Lodotra) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Niraparib for metastatic castration-resistant prostate cancer with DNA-repair anomalies Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Niraparib with abiraterone acetate and prednisone for metastatic castration resistant prostate cancer Abiraterone acetate (Zytiga; Yonsa) , Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate) , Prednisone (Decadron; Lodotra) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Nivolumab in combination with rucaparib for chemotherapy naive metastatic castration-resistant prostate cancer Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Nivolumab in combination with rucaparib for metastatic castration-resistant prostate cancer with prior chemotherapy Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Nivolumab with docetaxel for advanced castration-resistant prostate cancer Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Prostate cancer Male Reproductive Cancer 2021 View  |  Download
Olaparib for BRCAm or ATM mutated metastatic castration-resistant prostate cancer Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications